TY - JOUR
T1 - Endoscopic ultrasound-guided sampling for personalized pancreatic cancer treatment
AU - Iwasaki, Eisuke
AU - Fukuhara, Seiichiro
AU - Horibe, Masayasu
AU - Kawasaki, Shintaro
AU - Seino, Takashi
AU - Takimoto, Yoichi
AU - Tamagawa, Hiroki
AU - Machida, Yujiro
AU - Kayashima, Atsuto
AU - Noda, Marin
AU - Hayashi, Hideyuki
AU - Kanai, Takanori
N1 - Funding Information:
Funding: This work was supported by JSPS KAKENHI Grant Number 19K07739.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/3
Y1 - 2021/3
N2 - Pancreatic cancer is the most lethal solid malignancy, and the number of patients with pancreatic cancer is increasing. Systemic chemotherapies are often ineffective for such patients, and there is an urgent need for personalized medicine. Unlike other types of cancer, personalized treatments for pancreatic cancer are still in development. Consequently, pancreatic cancer is less sensitive to anticancer drugs and is often refractory to common treatments. Therefore, advances in personalized medicine for pancreatic cancer are necessary. This review examined advances in personalized medicine for pancreatic cancer, including the use of endoscopic ultrasound (EUS)-guided sampling. EUS-guided sampling is widely used for diagnosing pancreatic tumors and is expected to be applied to sampled tissues. Additionally, there has been an increase in clinical research using EUS-guided sampling. The combination of precision medicine using genomic testing and pharmacological profiles based on high-throughput drug sensitivity testing using patient-derived organoids is expected to revolutionize pancreatic cancer treatment.
AB - Pancreatic cancer is the most lethal solid malignancy, and the number of patients with pancreatic cancer is increasing. Systemic chemotherapies are often ineffective for such patients, and there is an urgent need for personalized medicine. Unlike other types of cancer, personalized treatments for pancreatic cancer are still in development. Consequently, pancreatic cancer is less sensitive to anticancer drugs and is often refractory to common treatments. Therefore, advances in personalized medicine for pancreatic cancer are necessary. This review examined advances in personalized medicine for pancreatic cancer, including the use of endoscopic ultrasound (EUS)-guided sampling. EUS-guided sampling is widely used for diagnosing pancreatic tumors and is expected to be applied to sampled tissues. Additionally, there has been an increase in clinical research using EUS-guided sampling. The combination of precision medicine using genomic testing and pharmacological profiles based on high-throughput drug sensitivity testing using patient-derived organoids is expected to revolutionize pancreatic cancer treatment.
KW - EUS-guided sampling
KW - Pancreatic cancer
KW - Patient-derived organoid
KW - Precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85115395171&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115395171&partnerID=8YFLogxK
U2 - 10.3390/diagnostics11030469
DO - 10.3390/diagnostics11030469
M3 - Review article
AN - SCOPUS:85115395171
SN - 2075-4418
VL - 11
JO - Diagnostics
JF - Diagnostics
IS - 3
M1 - 469
ER -
